“Why is my sex drive so low?”

It sounds like a simple question. But sexual desire is influenced by much more than one hormone, one medication or one stage of life.

Stress, sleep, mood, medications, menopause symptoms, sexual pain, relationship dynamics, physical health and changes in arousal can all affect how much interest someone feels in sex.

And having less desire than you once did does not automatically mean you have a sexual disorder.

For some women, however, low desire becomes persistent, occurs across situations and causes meaningful personal distress. That is where hypoactive sexual desire disorder, or HSDD, may enter the conversation.

The treatment landscape has also recently changed. In December 2025, the FDA expanded the indication for Addyi® (flibanserin) to include women under age 65 with acquired, generalized HSDD. That means eligible postmenopausal women under 65 are now included in its approved population. View the current Addyi prescribing information.

So what actually causes low libido in women, when might it be HSDD, and what treatment options exist in 2026?

The Short Answer

Low libido is a symptom. HSDD is a specific clinical condition.

Lower sexual interest can occur for many physical, psychological, medication-related and relationship reasons. Treatment therefore depends on what is contributing to the change, rather than simply trying to increase libido.

For the FDA-approved HSDD medications discussed in this article, acquired, generalized HSDD refers to low sexual desire that:

• developed after previously having no problem with sexual desire
• occurs regardless of the type of sexual activity, situation or partner
• causes marked distress or interpersonal difficulty
• is not better explained by another medical or psychiatric condition, relationship problems, or the effects of a medication or other drug

View the current FDA-approved Addyi indication.

That last point matters.

Not every woman with low desire has HSDD—and not every change in desire needs medication.

What Is Low Libido in Women?

Libido is another term for sexual desire or sexual interest.

But desire is only one part of sexual response.

Desire broadly describes interest or motivation for sexual activity.

Arousal includes the mental and physical responses associated with becoming sexually excited.

Orgasm is another distinct component of sexual response.

Sexual pain or discomfort can influence all of them.

These systems interact, but they do not always change together.

A woman can experience sexual desire but have difficulty becoming physically aroused. Another may experience physical arousal but little interest in sex. Someone else may have desire and arousal but difficulty reaching orgasm.

That is why the phrase “low libido” can describe very different experiences.

Related reading: PT-141 vs. Sildenafil vs. Tadalafil: What’s the Difference? explores why desire, arousal and physical sexual response should not automatically be treated as the same thing.

Is There a “Normal” Amount of Sexual Desire?

There is no universal amount of sexual interest—or frequency of sexual activity—that is normal for every woman.

Sexual desire varies considerably between people and can also change during different stages of life.

The more useful question is often not:

“Do I want sex often enough?”

but:

“Has my level of desire changed, and is that change troubling me?”

That distinction is important because personal distress is part of what separates a clinical condition such as HSDD from simply having less interest in sex than someone else—or less interest than cultural expectations suggest you should have.

What Is HSDD?

HSDD stands for hypoactive sexual desire disorder.

The current FDA labels for Addyi and Vyleesi use the term acquired, generalized HSDD.

Acquired

The decrease in desire developed after a period when sexual desire was not a problem.

Generalized

Low desire occurs regardless of the type of sexual activity, situation or partner.

Distressing

The change causes marked personal distress or interpersonal difficulty.

Not better explained by something else

For the FDA-approved indications, the low desire is not due to another medical or psychiatric condition, relationship problems, or the effects of a medication or other drug.

That is why HSDD is not simply another term for:

“I haven't felt very sexual lately.”

A proper evaluation looks at what changed and what may be contributing to it.

What Can Cause Low Libido in Women?

There is rarely one universal explanation.

Expert guidance on HSDD recommends a biopsychosocial approach—considering biological, psychological and interpersonal factors rather than assuming that low desire is simply a hormone problem. Read the ISSWSH Process of Care for HSDD.

Potential contributors include:

Stress, fatigue and poor sleep

Chronic stress, demanding schedules, caregiving responsibilities, disrupted sleep and exhaustion can all compete with sexual interest.

This can become particularly relevant during midlife, when work, family responsibilities, sleep disruption and physical changes may be occurring at the same time.

Depression, anxiety and emotional health

Mood and sexual desire can be closely connected.

Depression itself can affect sexual interest, while anxiety, sexual anxiety and other emotional factors may affect desire, arousal and the experience of intimacy.

Medications

Some medications can affect sexual function.

Certain antidepressants—particularly SSRIs and SNRIs—are well known for potentially affecting sexual desire, arousal or orgasm in some people.

A medication review can therefore be an important part of evaluating a change in libido.

That does not mean someone should stop an antidepressant or another prescription medication because of a suspected sexual side effect. Medication changes should be discussed with the healthcare professional managing that treatment.

Relationship and sexual context

Relationship conflict, loss of emotional connection, changes in attraction, a partner's sexual difficulties or changes in the circumstances surrounding sex can influence sexual desire.

This is one reason low desire occurring only with a particular partner or in a particular situation is different from the generalized low desire described in FDA-approved HSDD indications.

Pain, vaginal dryness or discomfort

It can be difficult to separate desire from what happens when sex becomes uncomfortable.

Genitourinary syndrome of menopause, or GSM, can involve vaginal dryness, irritation, reduced lubrication and pain with sexual activity.

If sexual activity becomes uncomfortable, avoidance or reduced interest may follow.

In that situation, addressing pain and vaginal health may be more relevant than immediately treating libido itself.

The Menopause Society provides additional information about GSM and sexual health.

Physical health

Chronic illness, cancer and cancer treatment, neurological conditions and many other changes in physical health can affect sexual wellbeing directly or indirectly.

That is another reason a clinician may consider broader health history before determining whether HSDD is the appropriate diagnosis.

Can Menopause Cause Low Libido?

Menopause can contribute to changes in sexual wellbeing, but menopause itself does not automatically cause HSDD.

The menopause transition can involve changes in:

• sleep
• hot flashes and night sweats
• mood
• energy
• vaginal dryness
• sexual discomfort
• body image
• relationships

Any combination of those factors may influence sexual interest.

For example, a woman who avoids sex because intercourse has become painful may understandably describe herself as having “no libido.”

But if the underlying issue is menopause-related vaginal dryness and pain, treating those symptoms may be an important part of addressing the sexual concern.

That is not necessarily the same clinical situation as acquired, generalized HSDD.

Does Low Estrogen Cause Low Libido?

It is more complicated than that.

Declining estrogen around menopause can contribute to vaginal and vulvar changes, dryness and pain. Hormone therapy may also be appropriate for certain menopause-related symptoms in appropriately selected patients.

But estrogen is not simply a universal treatment for low sexual desire.

A woman experiencing pain because of genitourinary syndrome of menopause may benefit from addressing vaginal symptoms. Someone with acquired, generalized HSDD may require a completely different assessment.

Reducing female sexual desire to:

“Your estrogen is low.”

misses much of the physiology and context involved.

Does Low Testosterone Cause Low Libido in Women?

This is another area where online information can become overly simplistic.

A testosterone blood test does not diagnose HSDD.

The International Society for the Study of Women's Sexual Health states that total testosterone concentration should not be used to diagnose HSDD.

Testosterone levels may be measured when testosterone treatment is being considered, primarily to establish a baseline and help monitor therapy—not to determine whether a woman “has testosterone deficiency.”

Read the ISSWSH testosterone clinical practice guideline.

So:

Low desire + a particular testosterone number does not automatically mean testosterone is the cause.

Female Libido Treatment Options in 2026

Treatment begins with identifying what is actually contributing to the change in desire.

Depending on the situation, care might involve addressing another health condition, reviewing medications, treating sexual pain or menopause symptoms, addressing psychological or relationship factors, or considering a treatment specifically for HSDD.

Before looking at each option in detail, here is the key distinction.

Addyi® — Flibanserin

Approved population: Women under 65 with acquired, generalized HSDD
How it is taken: Oral tablet once daily at bedtime
Treatment pattern: Daily, not on-demand
Important considerations: Alcohol timing, significant drug interactions, hepatic impairment, hypotension and syncope risk
FDA status: FDA-approved for its labeled HSDD population

Vyleesi® — Bremelanotide

Approved population: Premenopausal women with acquired, generalized HSDD
How it is taken: Subcutaneous injection
Treatment pattern: As needed, at least 45 minutes before anticipated sexual activity
Important considerations: Uncontrolled hypertension, cardiovascular disease, temporary blood-pressure changes and nausea
FDA status: FDA-approved for its labeled HSDD population

Testosterone

Population supported by the strongest evidence: Appropriately selected postmenopausal women with HSDD
How it is generally studied: Primarily systemic transdermal therapy
Treatment pattern: Ongoing therapy with clinical monitoring
Important considerations: Appropriate dosing and monitoring are important; long-term safety data remain limited
FDA status in the United States: Off-label; there is currently no FDA-approved testosterone product specifically indicated for women

These treatments are not interchangeable, and one is not simply a stronger version of another.

1. Address Underlying Contributors

Sometimes the most appropriate treatment is not a libido medication at all.

Depending on what is contributing, care may involve:

• reviewing medications associated with sexual side effects
• addressing depression or anxiety
• improving sleep
• treating vaginal dryness or sexual pain
• managing another medical condition
• addressing relationship or sexual-context concerns
• counseling, sex therapy or psychological approaches when appropriate

The goal is to avoid assuming that every complaint of low desire has the same biological cause.

2. Flibanserin — Addyi®

One of the biggest recent changes in women's sexual medicine involves flibanserin, sold as Addyi.

Until December 2025, its U.S. indication was limited to premenopausal women.

The current FDA-approved indication now covers women less than 65 years of age with acquired, generalized HSDD. This includes eligible naturally postmenopausal women under 65. The current prescribing information identifies the indication change as a major revision made in December 2025.

View the current Addyi prescribing information.

How Is Addyi Taken?

Addyi is taken once daily at bedtime.

It is not an on-demand medication taken immediately before anticipated sexual activity.

The prescribing information states that treatment should be discontinued after eight weeks if there is no improvement in HSDD symptoms.

Important Addyi Safety Considerations

Addyi has important interactions and precautions.

Taking Addyi and alcohol close together can increase the risk of severe low blood pressure and fainting. Current prescribing information instructs patients to:

• wait at least two hours after consuming one or two standard alcoholic drinks before taking Addyi at bedtime
• skip the evening dose after consuming three or more standard alcoholic drinks
• avoid alcohol until the following day after taking Addyi

Moderate or strong CYP3A4 inhibitors and hepatic impairment are contraindications.

Common adverse reactions reported in clinical trials include dizziness, sleepiness, nausea, fatigue, insomnia and dry mouth.

Addyi is not indicated to enhance sexual performance.

3. Bremelanotide — Vyleesi®

Bremelanotide is another FDA-approved HSDD treatment, but its approved population is different.

Vyleesi remains indicated for premenopausal women with acquired, generalized HSDD.

It is not FDA-approved for postmenopausal women, men or enhancement of sexual performance.

View the current Vyleesi prescribing information.

How Is Vyleesi Used?

FDA-approved Vyleesi is a 1.75 mg subcutaneous injection administered as needed at least 45 minutes before anticipated sexual activity.

Current prescribing information states:

• no more than one dose within 24 hours
• more than eight doses per month is not recommended
• treatment should be discontinued after eight weeks if symptoms have not improved

Important Vyleesi Safety Considerations

Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.

It can temporarily increase blood pressure and decrease heart rate after each dose. Those changes usually resolve within approximately 12 hours.

Nausea was the most commonly reported adverse reaction in phase 3 placebo-controlled trials, occurring in 40% of Vyleesi-treated patients compared with 1.3% receiving placebo.

What About PT-141?

PT-141 is a name used in earlier clinical research for bremelanotide.

But there is an important formulation distinction.

FDA-approved Vyleesi is a specific subcutaneous bremelanotide injection.

A compounded PT-141 film, troche, nasal preparation or other formulation is not the FDA-approved Vyleesi product.

Different routes and formulations should not automatically be assumed to have identical absorption, dosing, safety or clinical outcomes.

Research involving Vyleesi therefore should not automatically be interpreted as evidence for every product containing compounded PT-141.

For a deeper explanation, see PT-141 vs. Sildenafil vs. Tadalafil: What’s the Difference?.

4. Testosterone for HSDD

Testosterone occupies a different position in women's sexual medicine.

Expert consensus identifies HSDD in appropriately selected postmenopausal women as the primary evidence-based indication for testosterone therapy in women.

However, there is currently no FDA-approved testosterone product specifically indicated for women in the United States. When prescribed for female HSDD, testosterone is therefore used off-label.

Read the Global Consensus Position Statement on testosterone therapy for women.

The ISSWSH clinical practice guideline recommends considering testosterone only after a proper biopsychosocial assessment and after potentially modifiable contributors have been evaluated.

Evidence has primarily supported systemic transdermal testosterone at doses intended to maintain concentrations within the physiologic premenopausal female range.

Long-term safety data remain limited.

And one point is worth repeating:

A testosterone level should not be used by itself to diagnose HSDD.

5. Treating Menopause-Related Sexual Pain or Dryness

Sometimes reduced interest in sex is closely tied to discomfort rather than a primary desire disorder.

For women with genitourinary syndrome of menopause, treatment options may include vaginal moisturizers and lubricants and, when medically appropriate, prescription therapies such as local vaginal estrogen, vaginal DHEA or ospemifene.

These treatments address vaginal or vulvar symptoms and sexual pain.

They are not simply medications for HSDD.

That distinction matters because improving comfort can change someone's sexual experience without directly treating sexual desire itself.

6. Counseling, Sex Therapy and Psychological Approaches

Sexual desire is influenced by context as well as biology.

For some women, counseling, sex therapy, cognitive-behavioral approaches or mindfulness-based approaches may form part of treatment—particularly when stress, anxiety, relationship dynamics or sexual concerns are contributing.

This is why expert guidance uses a biopsychosocial framework rather than treating female desire as a single hormone or neurotransmitter problem.

What Changed for Female Libido Treatment in 2026?

Three points are particularly important in the current U.S. treatment landscape.

Addyi Now Includes Eligible Postmenopausal Women Under 65

The December 2025 FDA indication change expanded flibanserin from its previous premenopausal-only indication to women under 65 with acquired, generalized HSDD.

That is a meaningful change for women in midlife and after menopause who previously fell outside the FDA-approved population.

Vyleesi Remains Limited to Premenopausal Women

The current Vyleesi indication remains premenopausal women with acquired, generalized HSDD.

It is not indicated for postmenopausal women.

Testosterone Remains Off-Label in the United States

Evidence-based expert guidance supports testosterone as a potential option for appropriately selected postmenopausal women with HSDD.

But as of August 2026, there is still no FDA-approved testosterone formulation specifically indicated for women in the United States.

The treatment landscape has expanded, but age, menopausal status, symptoms, health history and the reason for low desire still matter.

Which Treatment Is Best for Low Libido in Women?

There is no treatment that is best for every woman.

Consider three different situations.

One woman may have little interest in sex because intercourse became painful after menopause.

Another may have acquired, generalized low desire that causes distress even though physical sexual function and her relationship are otherwise unchanged.

A third may notice that her sexual interest changed soon after beginning a medication that can affect sexual function.

All three may say:

“My sex drive is gone.”

But they may not have the same underlying problem.

And the appropriate treatment may therefore be completely different.

That is why understanding the pattern comes before choosing the treatment.

Frequently Asked Questions

Why Is My Sex Drive Suddenly Low?

A change in sexual desire can have many potential contributors, including stress, fatigue, mood changes, medications, relationship factors, menopause symptoms, sexual pain and physical-health changes.

A persistent or troubling change may warrant an evaluation rather than automatically assuming it is part of aging.

Is Low Libido Normal During Menopause?

Sexual interest can change around menopause, but there is no rule that women should lose sexual desire after menopause.

Sleep problems, hot flashes, vaginal dryness, pain, body-image changes, mood, medications and relationship factors can all influence sexual wellbeing.

What Is the Difference Between Low Libido and HSDD?

Low libido simply describes relatively low sexual desire.

Acquired, generalized HSDD involves low desire that causes meaningful distress or interpersonal difficulty, developed after previously normal desire, occurs across situations and partners, and is not better explained by another medical or psychiatric condition, relationship problems or medication effects.

Is Addyi Approved for Postmenopausal Women?

Yes, for eligible women under age 65.

The FDA expanded Addyi's indication in December 2025 to women under 65 with acquired, generalized HSDD. This includes eligible naturally postmenopausal women under age 65.

View the current Addyi label.

Is Vyleesi Approved After Menopause?

No.

The current FDA-approved Vyleesi indication is for premenopausal women with acquired, generalized HSDD. It is not indicated for postmenopausal women.

Is PT-141 the Same as Vyleesi?

PT-141 is a name used for bremelanotide in earlier research, and bremelanotide is the active ingredient in Vyleesi.

However, Vyleesi is a specific FDA-approved subcutaneous injection. Compounded PT-141 preparations in other dosage forms are not the FDA-approved Vyleesi product.

Can Antidepressants Lower Female Libido?

Certain antidepressants, particularly SSRIs and SNRIs, can affect sexual desire and other aspects of sexual function in some patients.

A prescription medication should not be stopped or changed without discussing it with the healthcare professional managing the treatment.

Does a Low Testosterone Result Mean I Have HSDD?

No.

Expert guidelines specifically state that total testosterone concentration should not be used to diagnose HSDD.

Diagnosis requires assessment of symptoms, distress and other possible contributors.

Can Testosterone Be Prescribed to Women for Low Libido?

Testosterone may be considered off-label for appropriately selected postmenopausal women with HSDD after a proper clinical assessment.

Expert consensus supports this use, but there is currently no FDA-approved testosterone product specifically indicated for women in the United States.

Does Viagra Treat Low Libido in Women?

Sildenafil is not FDA-approved as a treatment for HSDD or low sexual desire in women.

Sexual desire and genital arousal are not the same process, which is one reason medications acting primarily on blood-flow pathways should not automatically be considered treatments for low desire.

Can GLP-1 Medications Affect Female Libido?

Research has not established a predictable effect of GLP-1–based medications on sexual desire. Changes in libido and other aspects of sexual function are being studied, but current evidence remains limited and mixed.

Read more: Do GLP-1 Medications Affect Your Sex Drive?

When Low Desire Is Troubling, Understanding the Pattern Matters

Low sexual desire is not always a condition that requires treatment.

But if you have noticed persistent low desire that is troubling you, you can complete a private online health evaluation through AmalfiDuo.

AmalfiDuo Sexual Wellness Programs

If you’re exploring ways to support your sexual wellness, AmalfiDuo offers private, provider-guided care programs for adults.

Explore available programs and complete a private online health evaluation if you find an option that may be right for you. A licensed clinician will review your health information to determine whether treatment is appropriate.

Explore Sexual Wellness Programs

A prescription is never guaranteed.

‍

‍

References

1. Addyi® (flibanserin) — U.S. Prescribing Information. DailyMed, U.S. National Library of Medicine. Current labeling includes the December 2025 indication update.
2. Vyleesi® (bremelanotide injection) — U.S. Prescribing Information. DailyMed, U.S. National Library of Medicine.
3. Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clinic Proceedings. 2018;93(4):467–487.
4. Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. The Journal of Sexual Medicine. 2021.
5. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429–434.
6. Goldstein I, Kim NN, Clayton AH, et al. Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health Expert Consensus Panel Review. Mayo Clinic Proceedings. 2017;92(1):114–128.
7. Sexual Health. The Menopause Society.
8. Genitourinary Syndrome of Menopause. The Menopause Society.

‍

This article is provided for general educational purposes only and is not a substitute for individualized medical advice, diagnosis or treatment. Always discuss prescription medications and changes in sexual health with a qualified healthcare professional. AmalfiDuo Journal articles are written by AmalfiDuo Editorial and are not medically reviewed — see our Editorial Policy.

Addyi® and Vyleesi® are trademarks of their respective owners. AmalfiDuo is not affiliated with or endorsed by the owners or manufacturers of these brands.

‍